Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASE Technology Holding Co Ltd (ASX) vs Danaher Corporation (DHR) Price & Performance

ASE Technology Holding Co LtdTrade
Danaher CorporationTrade

Price performance (Past 24H)

Key statistics

ASE Technology Holding Co Ltd vs Danaher Corporation — how do they compare? ASE Technology Holding Co Ltd trades at $39.59 (market cap $85.75B), while Danaher Corporation trades at $207.23 (market cap $145.83B). The key difference: Danaher Corporation is the larger of the two by market cap, and ASE Technology Holding Co Ltd pays the higher dividend (1.08%). Which is the better fit depends on your goals.

ASXDHR
Market Cap
$85.75B$145.83B
Sector
TechnologyHealth
52-Week High
$45.12$242.05
52-Week Low
$9.63$161.91
Enterprise Value
$90.15B$168.04B
Dividend Yield
1.08%0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASE Technology Holding Co Ltd

ASE Technology Holding (ASX) trades at $37.59, up 0.53% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, exceeding expectations, and announced a $10.5 billion capital expenditure increase for AI-driven semiconductor demand (Reuters, 2026-07-30). Financials show revenue growth to $645.39 billion in 2025 and a net income margin of 8.46%, though valuation ratios like P/E of 47.78 appear elevated.

Outlook is positive due to AI capacity expansion and robust institutional interest, with 80% analyst buy ratings. Risks include high valuation sensitivity and execution challenges from increased capital spending. The stock's momentum is supported by earnings growth, but investors should monitor margin sustainability amid competitive pressures.

Danaher Corporation

Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.

The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASE Technology Holding Co Ltd

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Read more on ASX

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR